Name: Rociletinib
CAS#: 1374640-70-6
Chemical Formula: C27H28F3N7O3
Exact Mass: 555.22057
Molecular Weight: 555.55
Elemental Analysis: C, 58.37; H, 5.08; F, 10.26; N, 17.65; O, 8.64
We produce Rociletinib, AVL-301, CO1686, 1374640-70-6 in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
Rociletinib, AVL-301, CO1686, 1374640-70-6 Intermediates, we have 8; Rociletinib, AVL-301, CO1686, 1374640-70-6 Impurity we have 10, all from GMP, FDA plant.
Now Rociletinib, AVL-301, CO1686, 1374640-70-6 DMF document is preparing.
Until 2016, Aug, Rociletinib, AVL-301, CO1686, 1374640-70-6 more than produced 25kg API, 120kg Intermediates
Rociletinib AVL-301; CO-1686 1374640-70-6(free base)
Rociletinib AVL-301; CO-1686 1446700-26-0(Hydrobromide)
Rociletinib Intermediates Tert-butyl (3-((2-chloro-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)carbamate 1374507-23-9
Rociletinib Intermediates Tert-butyl (3-aminophenyl)carbamate 68621-88-5
Rociletinib Intermediates 1-(4-(4-amino-3-methoxyphenyl)piperazin-1-yl)ethanone 1021426-42-5
GMP PRODUCE:
Alectinib;Veliparib;Acalabrutinib;Venetoclax;Sotagliflozin;Ledipasvir;LX1606;Anacetrapib;Abemaciclib
Description: Rociletinib, also known as AVL-301 and CO1686, is an orally available small molecule, irreversible inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. EGFR inhibitor CO-1686 binds to and inhibits mutant forms of EGFR, including T790M, thereby leading to cell death of resistant tumor cells. Compared to other EGFR inhibitors, CO-1686 inhibits T790M, a secondary acquired resistance mutation, as well as other mutant EGFRs and may have therapeutic benefits in tumors with T790M-mediated resistance to other EGFR tyrosine kinase inhibitors.
Synonym: CO1686; CO-1686; CO 1686; AVL301; AVL 301; AVL-301; CNX419; CNX 419; CNX-419; Rociletinib.
IUPAC/Chemical Name: N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide
SMILES Code: C=CC(NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(C)=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1)=O
1: Liu SV, Subramaniam D, Cyriac GC, Abdul-Khalek FJ, Giaccone G. Emerging protein kinase inhibitors for non-small cell lung cancer. Expert Opin Emerg Drugs. 2014 Mar;19(1):51-65. doi: 10.1517/14728214.2014.873403. Epub 2013 Dec 20. PubMed PMID: 24354593.
CAS#: 1374640-70-6
Chemical Formula: C27H28F3N7O3
Exact Mass: 555.22057
Molecular Weight: 555.55
Elemental Analysis: C, 58.37; H, 5.08; F, 10.26; N, 17.65; O, 8.64
We produce Rociletinib, AVL-301, CO1686, 1374640-70-6 in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
Rociletinib, AVL-301, CO1686, 1374640-70-6 Intermediates, we have 8; Rociletinib, AVL-301, CO1686, 1374640-70-6 Impurity we have 10, all from GMP, FDA plant.
Now Rociletinib, AVL-301, CO1686, 1374640-70-6 DMF document is preparing.
Until 2016, Aug, Rociletinib, AVL-301, CO1686, 1374640-70-6 more than produced 25kg API, 120kg Intermediates
Rociletinib AVL-301; CO-1686 1374640-70-6(free base)
Rociletinib AVL-301; CO-1686 1446700-26-0(Hydrobromide)
Rociletinib Intermediates Tert-butyl (3-((2-chloro-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)carbamate 1374507-23-9
Rociletinib Intermediates Tert-butyl (3-aminophenyl)carbamate 68621-88-5
Rociletinib Intermediates 1-(4-(4-amino-3-methoxyphenyl)piperazin-1-yl)ethanone 1021426-42-5
GMP PRODUCE:
Alectinib;Veliparib;Acalabrutinib;Venetoclax;Sotagliflozin;Ledipasvir;LX1606;Anacetrapib;Abemaciclib
2016 Mumbai CPHI, Hope to meet!
2016 Barcelona CPHI, Hope to meet!
2016 Korea(한국) CPHI, C40, Welcome!
2016 Shanghai CPHI, W5C47, Welcome!
EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
辦公室: 0086-531-69905422-806(直通)
攜帶番號 & WhatsApp: +8618653174435
Skype: willgutian
Synonym: CO1686; CO-1686; CO 1686; AVL301; AVL 301; AVL-301; CNX419; CNX 419; CNX-419; Rociletinib.
IUPAC/Chemical Name: N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide
SMILES Code: C=CC(NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(C)=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1)=O
1: Liu SV, Subramaniam D, Cyriac GC, Abdul-Khalek FJ, Giaccone G. Emerging protein kinase inhibitors for non-small cell lung cancer. Expert Opin Emerg Drugs. 2014 Mar;19(1):51-65. doi: 10.1517/14728214.2014.873403. Epub 2013 Dec 20. PubMed PMID: 24354593.
